GlassScriptPhysician profile
Nancey Mae Hahn
NPI 1518128024
$2,410.74
in general payments reported to CMS, 2019-2025
30 companies · $393 in 2025
The $393 reported for 2025 was more than what 75% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $578 · 2020: $121 · 2021: $482 · 2022: $187 · 2023: $410 · 2024: $240 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $982 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $982.44 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $408.45 | 2019-2025 | |
| Aspira Women'S Health INC | $280.49 | 2019-2021 | |
| Astellas Pharma US INC | $186.68 | 2019-2025 | Veozah |
| Mayne Pharma Commercial LLC | $153.99 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $135.34 | 2023-2025 | Myfembree |
| Applied Medical Resources Corporation | $124.99 | 2019 | |
| Caldera Medical, INC | $124.36 | 2023 | Desara |
| Pfizer INC. | $96.84 | 2021-2024 | |
| Allergan, INC. | $83.56 | 2019-2020 | |
| Exeltis, USA INC. | $83.29 | 2020-2023 | Slynd |
| Conmed Corporation | $81.73 | 2019 | |
| Coopersurgical, INC. | $76.49 | 2021-2025 | Paragard T 380a |
| Smith+Nephew, INC. | $69.84 | 2019-2024 | Stravix Pl, Grafix Pl, Stravix Mesh |
| Millicent US INC | $56.47 | 2024-2025 | Intrarosa, Femlyv, Femring |
| Therapeuticsmd, INC. | $47.42 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $46.42 | 2025 | Myosure Tissue Removal Device, Aptima, Thinprep 2000 Processor |
| Daiichi Sankyo INC. | $44.33 | 2019 | |
| Mylan Pharmaceuticals INC. | $43.79 | 2019-2022 | |
| Novo Nordisk INC | $42.82 | 2023-2024 | |
| Amag Pharmaceuticals, INC. | $37.11 | 2019-2020 | |
| Shield Therapeutics INC | $28.18 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.28 | 2019 | |
| Renovia INC | $23.02 | 2021 | |
| Amgen INC. | $19.96 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $17.64 | 2025 | |
| Merck Sharp & Dohme LLC | $16.11 | 2020 | |
| Vertical Pharmaceuticals, LLC | $15.50 | 2019 | |
| Duchesnay USA Incorporated | $14.31 | 2019 | |
| Myovant Sciences INC. | $12.99 | 2021 | |
| Mission Pharmacal Company | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancey Hahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.